Charles River Laboratories International Inc.

Find Ratings Reports
CRL : NYSE : Commercial Services
$108.11 | %
Today's Range: 0.0 - 0.0
Avg. Daily Volume: 378200.0
02/16/18 - 4:02 PM ET

Financial Analysis


CHARLES RIVER LABS INTL INC's gross profit margin for the fourth quarter of its fiscal year 2017 has significantly decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. CHARLES RIVER LABS INTL INC has average liquidity. Currently, the Quick Ratio is 1.28 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.

During the same period, stockholders' equity ("net worth") has increased by 24.89% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY17 Q4 FY16
Net Sales ($mil)478.48466.79
EBITDA ($mil)0.0104.95
EBIT ($mil)64.5569.41
Net Income ($mil)-29.8544.68


Balance Sheet Q4 FY17 Q4 FY16
Cash & Equiv. ($mil)163.79121.93
Total Assets ($mil)2929.922711.8
Total Debt ($mil)1145.11235.01
Equity ($mil)1045.08836.77


Profitability Q4 FY17 Q4 FY16
Gross Profit Margin32.8743.92
EBITDA Margin0.022.48
Operating Margin13.4914.87
Sales Turnover0.630.62
Return on Assets4.215.7
Return on Equity11.8118.46
Debt Q4 FY17 Q4 FY16
Current Ratio1.781.53
Debt/Capital0.520.6
Interest Expense7.727.51
Interest Coverage8.369.24


Share Data Q4 FY17 Q4 FY16
Shares outstanding (mil)47.3247.36
Div / share0.00.0
EPS-0.630.93
Book value / share22.0817.67
Institutional Own % n/a n/a
Avg Daily Volume387562.0406812.0

Valuation


HOLD. The current P/E ratio indicates a significant discount compared to an average of 134.05 for the Life Sciences Tools & Services industry and a significant premium compared to the S&P 500 average of 25.51. To use another comparison, its price-to-book ratio of 4.97 indicates a significant premium versus the S&P 500 average of 3.26 and a significant discount versus the industry average of 6.61. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, CHARLES RIVER LABS INTL INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
CRL 43.00 Peers 134.05   CRL 16.41 Peers 27.37

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

CRL is trading at a significant discount to its peers.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

CRL is trading at a significant discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
CRL 16.73 Peers 30.29   CRL 0.34 Peers 4.39

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

CRL is trading at a significant discount to its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

CRL trades at a significant discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
CRL 4.97 Peers 6.61   CRL -20.81 Peers 14.20

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

CRL is trading at a discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, CRL is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
CRL 2.79 Peers 8.76   CRL 10.47 Peers 22.05

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

CRL is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

CRL significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades